Composition and method for treating peripheral t-cell lymphoma and cutaneous t-cell lymphoma
US-2020289520-A1 · Sep 17, 2020 · US
Dual selective PI3 delta and gamma kinase inhibitors
US11466006B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11466006-B2 |
| Application number | US-202016865034-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 1, 2020 |
| Priority date | Jun 7, 2013 |
| Publication date | Oct 11, 2022 |
| Grant date | Oct 11, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to dual delta (δ) and gamma (γ) PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of Pi3K kinase mediated diseases or disorders with them.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating T-cell lymphoma in a patient in need thereof, the method comprising administering to the patient an effective amount of (S)-2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one or a pharmaceutically acceptable salt thereof. 2. A method of treating T-cell lymphoma in a patient in need thereof, the method comprising administering to the patient an effective amount of a compound that is (S)-2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one or a pharmaceutically acceptable salt thereof, wherein the compound contains less than about 5% by weight of (R)-2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one or a pharmaceutically acceptable salt thereof. 3. The method of claim 2 , wherein the compound contains less than about 2.5% by weight of (R)-2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one or a pharmaceutically acceptable salt thereof. 4. The method of claim 2 , wherein the compound contains less than about 1% by weight of (R)-2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one or a pharmaceutically acceptable salt thereof. 5. The method of claim 2 , wherein the compound contains less than about 0.1% by weight of (R)-2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one or a pharmaceutically acceptable salt thereof. 6. The method of claim 1 , wherein the patient is a human patient. 7. The method of claim 2 , wherein the patient is a human patient. 8. The method of claim 3 , wherein the patient is a human patient. 9. The method of claim 4 , wherein the patient is a human patient. 10. The method of claim 5 , wherein the patient is a human patient.
Assignees
Inventors
Classifications
two oxygen atoms · CPC title
Drugs for disorders of the respiratory system · CPC title
- C07D473/34Primary
attached in position 6, e.g. adenine · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11466006B2 cover?
- The present invention relates to dual delta (δ) and gamma (γ) PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of Pi3K kinase mediated diseases or disorders with them.
- Who is the assignee on this patent?
- Rhizen Pharmaceuticals Sa, Rhizen Pharmaceuticals Ag
- What technology area does this patent fall under?
- Primary CPC classification C07D473/34. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Oct 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).